EX-99.1 2 lpth_ex991.htm PRESS RELEASE lpth_ex991.htm

  EXHIBIT 99.1

 

LightPath Technologies Reports Third Quarter Fiscal 2025 Financial Results

 

ORLANDO, FL – May 15, 2025 – LightPath Technologies, Inc. (NASDAQ: LPTH) (“LightPath,” the “Company,” “we,” or “our”), a leading provider of next-generation optics and imaging systems for both defense and commercial applications, today announced financial results for its fiscal third quarter ended March 31, 2025.

 

Financial Summary:

 

 

 

Three Months Ended March 31,

 

$ in millions

 

2025

 

 

2024

 

 

% Change

 

Revenue

 

$ 9.2

 

 

$ 7.7

 

 

 

19.1 %

Gross Profit

 

$ 2.7

 

 

$ 1.6

 

 

 

65.9 %

Operating Expenses

 

$ 6.0

 

 

$ 4.2

 

 

 

44.3 %

Net Income (Loss)

 

($3.6)

 

 

($2.6)

 

 

 

37.1 %

Adj. EBITDA* (non-GAAP)

 

($2.0)

 

 

($1.5)

 

 

31.3

%

 

Third Quarter Fiscal 2025 & Subsequent Highlights:

 

 

·

Closed the acquisition of G5 Infrared (“G5”), a leading high-end infrared camera systems manufacturer, part of LightPath’s strategic vision to become a leading vertically-integrated infrared imaging solutions provider.

 

·

Awarded an initial $2.2 million engineering development model (EDM) order for infrared cameras by L3Harris Technologies to support the Navy's Shipboard Panoramic Electro-Optic/Infrared (SPEIR) Program.

 

·

Received a $4.8 million initial qualification order for infrared cameras with a new defense industry customer, for planned delivery in calendar year 2025.

 

·

Secured $4.9 million order for cooled infrared cameras with existing defense customer, for planned delivery in fiscal 2026.

 

·

Participated in leading industry and investor conferences including the Photonics Spectra Infrared Imaging Summit 2025, SPIE Defense + Commercial Sensing, Advanced Infrared Solutions at 2025 Border Security Expo, 27th Annual Needham Growth Conference, and Sequire Investor Summit Puerto Rico.

 

Management Commentary

 

Sam Rubin, President and Chief Executive Officer of LightPath, said: “The closing of our acquisition of G5 Infrared, and the subsequent three significant orders for this new subsidiary, helped to accelerate execution of our strategic vision to become a leading vertically-integrated infrared imaging solutions provider in the $9 billion infrared imaging market. G5 provides a highly incremental offering to LightPath, providing a broad range of cooled infrared camera solutions and assemblies, ranging from high performance mid wave zoom thermal imaging camera systems to thin film deposition services on a variety of infrared substrates, all of which are complementary to our line of uncooled infrared cameras, infrared optics and infrared materials.

 

 
1

 

 

“G5’s significant pipeline of new business opportunities, with multiple program awards expected to begin production in the next two years, was highlighted recently by three new orders that validate our accretive acquisition. A $4.8 million initial qualification order with a new defense industry customer and a $4.9 million follow-on order with an existing defense industry customer was followed by an initial $2.2 million engineering development model order by L3Harris Technologies – all of which were for infrared cameras from our growing portfolio of cooled and uncooled camera solutions. G5's revenue is primarily driven by established multi-year contracts and multiple programs of record in shipboard long-range surveillance, border security, and counter UAS systems, as well as recurring federal, naval, and law enforcement programs. We expect to add significant value beyond G5’s initial accretive revenue stream and believe the acquisition will continue to drive future growth with its higher average selling price and higher-margin cooled infrared camera offerings, incremental products, as well as notable operational synergies – such as integrating their offerings with our proprietary BlackDiamond™ glass and in-house optics manufacturing capabilities.

 

“Looking ahead, we expect continued momentum for our product portfolio and market potential with our Germanium-free BlackDiamond™ infrared imaging solutions. With supply chain issues plaguing competing Germanium based solutions – such as China's recent ban on the export of Germanium to the United States – our BlackDiamond products are becoming increasingly important to customers. While the China ban has of course impacted the small proportion of our legacy business that still leverages Germanium, we continue to transition our business to utilize our BlackDiamond™ solutions.

 

“We are moving forward with key defense programs, including our bid to produce a design of a major missile program for the U.S. Army with Lockheed Martin. We are now starting to deliver flightworthy hardware for implementation into Lockheed Martin's initial live program test units and believe the U.S. Army could potentially make a contractor selection decision late this year or early next year. With the integration of G5, we believe we are well positioned to be the optical solutions provider of choice for high value customers with an accelerating pipeline of government and military projects with key defense customers,” concluded Rubin.

 

Third Quarter Fiscal 2025 Financial Results

 

Revenue for the third quarter of fiscal 2025 increased 19.1% to $9.2 million, as compared to $7.7 million in the same quarter of the prior fiscal year. Revenue was split amongst the Company’s product groups in the third quarter of fiscal 2025 as follows:

 

Product Group Revenue

($ in millions)**

Third Quarter of

Fiscal 2025

Third Quarter of

 Fiscal 2024

% Change

Infrared Components

$3.6

$3.6

0%

Visible Components

$2.8

$2.7

6%

Assemblies & Modules

$1.9

$0.8

123%

Engineering Services

$0.8

$0.5

54%

 

** Numbers may not foot due to rounding

 

Gross profit increased 65.9% to $2.7 million, or 29.1% of total revenues, in the third quarter of 2025, as compared to $1.6 million, or 20.9% of total revenues, in the same quarter of the prior fiscal year. The increase in gross margin as a percentage of revenue is primarily due to a more favorable product mix, with more revenue from assemblies and modules and engineering services, which typically have higher margins than infrared components.

 

 
2

 

 

Operating expenses increased 42.9% to $6.0 million for the third quarter of fiscal 2025, as compared to $4.2 million in the same quarter of the prior fiscal year. The increase was primarily due to higher legal and consulting fees related to business development and strategic initiatives, including expenses associated with the G5 acquisition, as well as increased sales and marketing spend to promote new products and an increase in materials spend for internally-funded new product development projects.

 

Net loss in the third quarter of fiscal 2025 totaled $3.6 million, or $0.09 per basic and diluted share, as compared to $2.6 million, or $0.07 per basic and diluted share, in the same quarter of the prior fiscal year.

 

Adjusted EBITDA* loss for the third quarter of fiscal 2025 was $2.0 million, compared to a loss of $1.5 million for the same period of the prior fiscal year.

 

Third Quarter Fiscal 2025 Earnings Call

 

Management will host an investor conference call at 5:00 p.m. Eastern time today, Thursday, May 15, 2025, to discuss the Company’s third quarter fiscal 2025 financial results, provide a corporate update, and conclude with Q&A from telephone participants. To participate, please use the following information:

Date: Thursday, May 15, 2025

Time: 5:00 p.m. Eastern time

U.S. Dial-in:

1-877-425-9470

International Dial-in: 1-201-389-0878

Conference ID: 13749941

Webcast: LPTH Q3 FY2025 Earnings Conference Call

 

Please join at least five minutes before the start of the call to ensure timely participation.

 

A playback of the call will be available through Thursday, May 29, 2025. To listen, please call 1-844-512-2921 within the United States and Canada or 1-412-317-6671 when calling internationally, using replay pin number 13749941. A webcast replay will also be available using the webcast link above.

 

About LightPath Technologies

 

LightPath Technologies, Inc. (NASDAQ: LPTH) is a leading provider of next-generation optics and imaging systems for both defense and commercial applications. As a vertically integrated solutions provider with in-house engineering design support, LightPath's family of custom solutions range from proprietary BlackDiamond™ chalcogenide-based glass materials – sold under exclusive license from the U.S. Naval Research Laboratory – to complete infrared optical systems and thermal imaging assemblies. The Company's primary manufacturing footprint is located in Orlando, Florida with additional facilities in Texas, New Hampshire, Latvia and China. To learn more, please visit www.lightpath.com.

 

 
3

 

 

*Use of Non-GAAP Financial Measures

 

To provide investors with additional information regarding financial results, this press release includes references to EBITDA and adjusted EBITDA, which are non-GAAP financial measures. The Company calculates EBITDA by adjusting net income to exclude net interest expense, income tax expense or benefit, depreciation, and amortization. We also calculate adjusted EBITDA, which excludes: (1) the effect of the non-cash income or expense associated with the mark-to-market adjustments, related to the warrants; and (2) the loss on extinguishment of debt. The fair value of the warrants is re-measured each reporting period until the warrants are either exercised or expired (which expiration occurs on February 18, 2031).

 

A "non-GAAP financial measure" is generally defined as a numerical measure of a company's historical or future performance that excludes or includes amounts, or is subject to adjustments, so as to be different from the most directly comparable measure calculated and presented in accordance with GAAP. The Company's management believes that these non-GAAP financial measures, when considered together with the GAAP financial measures, provide information that is useful to investors in understanding period-over-period operating results separate and apart from items that may, or could, have a disproportionately positive or negative impact on results in any particular period. Management also believes that these non-GAAP financial measures enhance the ability of investors to analyze underlying business operations and understand performance. In addition, management may utilize these non-GAAP financial measures as guides in forecasting, budgeting, and planning. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures presented in accordance with GAAP. A reconciliation of these non-GAAP financial measures with the most directly comparable financial measures calculated in accordance with GAAP is presented in the table below.

  

LIGHTPATH TECHNOLOGIES, INC.

Reconciliation of Non-GAAP Financial Measures and Regulation G Disclosure

 

 

 

 

 

 

 

 

 

 

 

(unaudited)

 

 

 

Three Months Ended March 31,

 

 

Nine Months Ended March 31,

 

 

 

2025

 

 

2024

 

 

2025

 

 

2024

 

Net loss

 

$ (3,560,349 )

 

$ (2,597,534 )

 

$ (7,795,091 )

 

$ (5,653,573 )
Depreciation and amortization

 

 

1,463,150

 

 

 

1,042,850

 

 

 

3,356,752

 

 

 

2,985,850

 

Income tax provision

 

 

100,031

 

 

 

5,798

 

 

 

160,192

 

 

 

121,402

 

Interest expense

 

 

498,862

 

 

 

37,649

 

 

 

817,275

 

 

 

149,048

 

 EBITDA

 

$ (1,498,306 )

 

$ (1,511,237 )

 

$ (3,460,872 )

 

$ (2,397,273 )
Loss on extinguishment of debt

 

 

418,502

 

 

 

-

 

 

 

418,502

 

 

 

-

 

Change in fair value of warrant liability

 

 

(904,694 )

 

 

-

 

 

 

(904,694 )

 

 

-

 

Adjusted EBITDA

 

$ (1,984,498 )

 

$ (1,511,237 )

 

$ (3,947,064 )

 

$ (2,397,273 )
% of revenue

 

 

-22 %

 

 

-20 %

 

 

-16 %

 

 

-10 %

 

 
4

 

 

Forward-Looking Statements

 

This press release includes statements that constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "forecast," "guidance," "plan," "estimate," "will," "would," "project," "maintain," "intend," "expect," "anticipate," "prospect," "strategy," "future," "likely," "may," "should," "believe," "continue," "opportunity," "potential," and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, without limitation, statements regarding: (i) anticipated timing for program awards, as well as any resulting impact on our financial performance; (ii) the impact of the G5 acquisition on our business and results of operations; (iii) the performance of our product portfolio and expected market potential with our products and (iv) expectations regarding our ability to secure government and military projects with certain customers. These forward-looking statements are based on information available at the time the statements are made and/or management's good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in or suggested by the forward-looking statements.  Factors that could cause or contribute to such differences include, but are not limited to, the impact of varying demand for the Company products; the ability of the Company to obtain needed raw materials and components from its suppliers; the impact of tariffs and other governmental trade restrictions; actions governments, businesses, and individuals take in response to the pandemic, including restrictions on onsite commercial interactions; general economic uncertainty in key global markets and a worsening of global economic conditions or low levels of economic growth; geopolitical tensions, the Russian-Ukraine conflict, and the Hamas/ Israel war; the effects of steps that the Company could take to reduce operating costs; the inability of the Company to sustain profitable sales growth, convert inventory to cash, or reduce its costs to maintain competitive prices for its products; circumstances or developments that may make the Company unable to implement or realize the anticipated benefits, or that may increase the costs, of its current and planned business initiatives; and those factors detailed by the Company in its public filings with the Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K and other filings with the SEC. Should one or more of these risks, uncertainties, or facts materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by the forward-looking statements contained herein. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Except as required under the federal securities laws and the rules and regulations of the SEC, we do not have any intention or obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.

 

Contact

Lucas A. Zimmerman

MZ Group – MZ North America

[email protected]

949-259-4987

 

 
5

 

 

LIGHTPATH TECHNOLOGIES, INC.

 

Condensed Consolidated Balance Sheets

(unaudited)

 

 

 

March 31,

 

 

June 30,

 

Assets

 

2025

 

 

2024

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$ 6,478,885

 

 

$ 3,480,268

 

Trade accounts receivable, net of allowance of $23,514 and $25,676

 

 

7,651,086

 

 

 

4,928,931

 

Inventories, net

 

 

12,687,225

 

 

 

6,551,059

 

Prepaid expenses and deposits

 

 

1,206,115

 

 

 

445,900

 

Other current assets

 

 

57,815

 

 

 

131,177

 

 Total current assets

 

 

28,081,126

 

 

 

15,537,335

 

 

 

 

 

 

 

 

 

 

Property and equipment, net

 

 

15,461,601

 

 

 

15,210,612

 

Operating lease right-of-use assets

 

 

6,457,530

 

 

 

6,741,549

 

Intangible assets, net

 

 

21,476,226

 

 

 

3,650,739

 

Goodwill

 

 

9,741,473

 

 

 

6,764,127

 

Deferred tax assets, net

 

 

123,000

 

 

 

123,000

 

Other assets

 

 

79,860

 

 

 

59,602

 

Total assets

 

$ 81,420,816

 

 

$ 48,086,964

 

Liabilities and Stockholders Equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$ 5,737,240

 

 

$ 3,231,713

 

Accrued liabilities

 

 

3,079,036

 

 

 

1,911,867

 

Accrued payroll and benefits

 

 

1,752,940

 

 

 

1,446,452

 

Operating lease liabilities, current

 

 

1,271,740

 

 

 

1,059,998

 

Loans payable, current portion

 

 

185,631

 

 

 

209,170

 

Finance lease obligation, current portion

 

 

203,954

 

 

 

177,148

 

 Total current liabilities

 

 

12,230,541

 

 

 

8,036,348

 

 

 

 

 

 

 

 

 

 

Deferred tax liabilities, net

 

 

1,498,479

 

 

 

326,197

 

Accrued liabilities, noncurrent

 

 

937,000

 

 

 

611,619

 

Finance lease obligation, less current portion

 

 

457,441

 

 

 

528,753

 

Operating lease liabilities, noncurrent

 

 

7,518,766

 

 

 

8,058,502

 

Loans payable, less current portion

 

 

4,693,444

 

 

 

325,880

 

Warrant liability

 

 

4,116,357

 

 

 

-

 

Total liabilities

 

 

31,452,128

 

 

 

17,887,299

 

 

 

 

 

 

 

 

 

 

Commitments and Contingencies

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Series G Convertible Preferred Stock; $0.01 par value

 

$ 34,399,622

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Stockholders equity:

 

 

 

 

 

 

 

 

Preferred stock: Series D, $.01 par value, voting;

 

 

 

 

 

 

 

 

500,000 shares authorized; none issued and outstanding

 

 

 

 

 

 

 

 

Common stock: Class A, $.01 par value, voting;

 

 

 

 

 

 

 

 

94,500,000 shares authorized;

 

 

 

 

 

 

 

 

42,893,563 and 39,254,643 shares issued and outstanding

 

 

428,936

 

 

 

392,546

 

Additional paid-in capital

 

 

238,327,729

 

 

 

245,140,758

 

Accumulated other comprehensive income

 

 

451,067

 

 

 

509,936

 

Accumulated deficit

 

 

(223,638,666 )

 

 

(215,843,575 )
Total stockholders equity

 

 

15,569,066

 

 

 

30,199,665

 

Total liabilities, convertible preferred stock and stockholders equity

 

$ 81,420,816

 

 

$ 48,086,964

 

 

 
6

 

 

 

LIGHTPATH TECHNOLOGIES, INC.

 

Condensed Consolidated Statements of Comprehensive Income (Loss)

(unaudited)

 

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

March 31,

 

 

March 31,

 

 

 

2025

 

 

2024

 

 

2025

 

 

2024

 

Revenue, net

 

$ 9,167,627

 

 

$ 7,699,175

 

 

$ 24,992,837

 

 

$ 23,092,060

 

Cost of sales

 

 

6,503,526

 

 

 

6,092,988

 

 

 

17,553,476

 

 

 

16,985,846

 

Gross profit

 

 

2,664,101

 

 

 

1,606,187

 

 

 

7,439,361

 

 

 

6,106,214

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative

 

 

4,448,359

 

 

 

3,171,770

 

 

 

11,075,005

 

 

 

8,691,395

 

New product development

 

 

757,938

 

 

 

569,962

 

 

 

1,998,775

 

 

 

1,817,598

 

Amortization of intangible assets

 

 

779,025

 

 

 

434,403

 

 

 

1,469,512

 

 

 

1,201,120

 

Loss on disposal of property and equipment

 

 

2,068

 

 

 

13,248

 

 

 

80,505

 

 

 

13,248

 

Total operating expenses

 

 

5,987,390

 

 

 

4,189,383

 

 

 

14,623,797

 

 

 

11,723,361

 

Operating loss

 

 

(3,323,289 )

 

 

(2,583,196 )

 

 

(7,184,436 )

 

 

(5,617,147 )

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense, net

 

 

(498,862 )

 

 

(37,649 )

 

 

(817,275 )

 

 

(149,048 )
Loss on extinguishment of debt

 

 

(418,502 )

 

 

-

 

 

 

(418,502 )

 

 

-

 

Change in fair value of warrant liability

 

 

904,694

 

 

 

-

 

 

 

904,694

 

 

 

-

 

Other income (expense), net

 

 

(124,359 )

 

 

29,109

 

 

 

(119,380 )

 

 

234,024

 

Total other income (expense), net

 

 

(137,029 )

 

 

(8,540 )

 

 

(450,463 )

 

 

84,976

 

Loss before income taxes

 

 

(3,460,318 )

 

 

(2,591,736 )

 

 

(7,634,899 )

 

 

(5,532,171 )
Income tax provision

 

 

100,031

 

 

 

5,798

 

 

 

160,192

 

 

 

121,402

 

Net loss

 

$ (3,560,349 )

 

$ (2,597,534 )

 

$ (7,795,091 )

 

$ (5,653,573 )

Foreign currency translation adjustment

 

 

120,572

 

 

 

(112,356 )

 

 

(58,869 )

 

 

22,409

 

Comprehensive loss

 

$ (3,439,777 )

 

$ (2,709,890 )

 

$ (7,853,960 )

 

$ (5,631,164 )

Loss per common share (basic)

 

$ (0.09 )

 

$ (0.07 )

 

$ (0.19 )

 

$ (0.15 )

Number of shares used in per share calculation (basic)

 

 

41,363,643

 

 

 

37,988,770

 

 

 

40,209,657

 

 

 

37,639,464

 

Loss per common share (diluted)

 

$ (0.09 )

 

$ (0.07 )

 

$ (0.19 )

 

$ (0.15 )

Number of shares used in per share calculation (diluted)

 

 

41,363,643

 

 

 

37,988,770

 

 

 

40,209,657

 

 

 

37,639,464

 

 

 
7

 

 

LIGHTPATH TECHNOLOGIES, INC.

Condensed Consolidated Statements of Changes in Stockholders' Equity

(unaudited)

 

 

 

Temporary Equity

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

Series G Convertible

 

 

Class A

 

 

Additional

 

 

Other

 

 

 

 

Total

 

 

 

Preferred Stock

 

 

Common Stock

 

 

Paid-in

 

 

Comphrehensive

 

 

Accumulated

 

 

Stockholders

 

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Income

 

 

Deficit

 

 

Equity

 

Balances at June 30, 2024

 

 

 

 

 

 

 

 

39,254,643

 

 

$ 392,546

 

 

$ 245,140,758

 

 

$ 509,936

 

 

$ (215,843,575 )

 

$ 30,199,665

 

Issuance of common stock for:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Employee Stock Purchase Plan

 

-

 

 

-

 

 

 

8,232

 

 

 

82

 

 

 

10,290

 

 

 

-

 

 

 

-

 

 

 

10,372

 

Exercise of Stock Options, RSUs & RSAs, net

 

-

 

 

-

 

 

 

70,309

 

 

 

703

 

 

 

(703 )

 

 

-

 

 

 

-

 

 

 

-

 

Issuance of common stock for acquisition of Visimid

 

-

 

 

-

 

 

 

279,553

 

 

 

2,796

 

 

 

318,562

 

 

 

-

 

 

 

-

 

 

 

321,358

 

Stock-based compensation on stock options, RSUs & RSAs

 

-

 

 

-

 

 

 

-

 

 

 

-

 

 

 

264,475

 

 

 

-

 

 

 

-

 

 

 

264,475

 

Foreign currency translation adjustment

 

-

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

271,594

 

 

 

-

 

 

 

271,594

 

Net loss 

 

-

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(1,622,745 )

 

 

(1,622,745 )

Balances at September 30, 2024

 

-

 

 

-

 

 

 

39,612,737

 

 

$ 396,127

 

 

$ 245,733,382

 

 

$ 781,530

 

 

$ (217,466,320 )

 

$ 29,444,719

 

Issuance of common stock for:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercise of Stock Options, RSUs & RSAs, net

 

-

 

 

-

 

 

 

229,097

 

 

 

2,291

 

 

 

(2,291 )

 

 

-

 

 

 

-

 

 

 

-

 

Shares issued as compensation

 

-

 

 

-

 

 

 

49,000

 

 

 

490

 

 

 

89,180

 

 

 

-

 

 

 

-

 

 

 

89,670

 

Stock-based compensation on stock options, RSUs & RSAs

 

-

 

 

-

 

 

 

-

 

 

 

-

 

 

 

231,581

 

 

 

-

 

 

 

-

 

 

 

231,581

 

Foreign currency translation adjustment

 

-

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(451,035 )

 

 

-

 

 

 

(451,035 )
Net loss 

 

-

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(2,611,997 )

 

 

(2,611,997 )

Balances at December 31, 2024

 

-

 

 

-

 

 

 

39,890,834

 

 

$ 398,908

 

 

$ 246,051,852

 

 

$ 330,495

 

 

$ (220,078,317 )

 

$ 26,702,938

 

Issuance of preferred stock under private equity placement, net of fees

 

 

255

 

 

 

20,968,590

 

 

 

-

 

 

 

-

 

 

 

(1,320,102 )

 

 

-

 

 

 

-

 

 

 

(1,320,102 )

Issuance of common stock for:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Employee Stock Purchase Plan

 

 

-

 

 

 

-

 

 

 

1,137

 

 

 

11

 

 

 

4,002

 

 

 

-

 

 

 

-

 

 

 

4,013

 

Exercise of Stock Options, RSUs & RSAs, net

 

 

-

 

 

 

-

 

 

 

238,641

 

 

 

2,387

 

 

 

788

 

 

 

-

 

 

 

-

 

 

 

3,175

 

Issuance of common stock for acquisition of Visimid

 

 

-

 

 

 

-

 

 

 

102,700

 

 

 

1,027

 

 

 

391,561

 

 

 

-

 

 

 

-

 

 

 

392,588

 

Issuance of common stock for acquisition of G5

 

 

-

 

 

 

-

 

 

 

1,972,501

 

 

 

19,725

 

 

 

4,852,343

 

 

 

-

 

 

 

-

 

 

 

4,872,068

 

Issuance of common stock under private equity placement, net of fees

 

 

-

 

 

 

-

 

 

 

687,750

 

 

 

6,878

 

 

 

1,584,014

 

 

 

-

 

 

 

-

 

 

 

1,590,892

 

Preferred cumulative dividends plus accretion

 

 

-

 

 

 

13,431,032

 

 

 

-

 

 

 

-

 

 

 

(13,431,032 )

 

 

-

 

 

 

-

 

 

 

(13,431,032 )

Stock-based compensation on stock options, RSUs & RSAs

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

194,303

 

 

 

-

 

 

 

-

 

 

 

194,303

 

Foreign currency translation adjustment

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

120,572

 

 

 

-

 

 

 

120,572

 

Net loss 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(3,560,349 )

 

 

(3,560,349 )
Balances at March 31, 2025 

 

 

255

 

 

$ 34,399,622

 

 

 

42,893,563

 

 

$ 428,936

 

 

$ 238,327,729

 

 

$ 451,067

 

 

$ (223,638,666 )

 

$ 15,569,066

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances at June 30, 2023 

 

 

 

 

 

 

 

 

 

 

37,344,739

 

 

$ 373,447

 

 

$ 242,808,771

 

 

$ 606,536

 

 

$ (207,836,229 )

 

$ 35,952,525

 

Issuance of common stock for:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Employee Stock Purchase Plan

 

 

 

 

 

 

 

 

 

 

14,607

 

 

 

146

 

 

 

19,573

 

 

 

-

 

 

 

-

 

 

 

19,719

 

Exercise of Stock Options, RSUs & RSAs, net

 

 

 

 

 

 

 

 

 

 

14,482

 

 

 

145

 

 

 

(145 )

 

 

-

 

 

 

-

 

 

 

 

 

Issuance of common stock for acquisition of Visimid

 

 

 

 

 

 

 

 

 

 

81,610

 

 

 

816

 

 

 

149,184

 

 

 

-

 

 

 

-

 

 

 

150,000

 

Stock-based compensation on stock options, RSUs & RSAs

 

 

 

 

 

 

 

 

 

 

-

 

 

 

-

 

 

 

240,075

 

 

 

-

 

 

 

-

 

 

 

240,075

 

Foreign currency translation adjustment

 

 

 

 

 

 

 

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(125,208 )

 

 

-

 

 

 

(125,208 )
Net loss 

 

 

 

 

 

 

 

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(1,342,376 )

 

 

(1,342,376 )

Balances at September 30, 2023

 

 

 

 

 

 

 

 

 

 

37,455,438

 

 

$ 374,554

 

 

$ 243,217,458

 

 

$ 481,328

 

 

$ (209,178,605 )

 

$ 34,894,735

 

Issuance of common stock for:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercise of Stock Options, RSUs & RSAs, net

 

 

 

 

 

 

 

 

 

 

93,940

 

 

 

940

 

 

 

(940 )

 

 

-

 

 

 

-

 

 

 

-

 

Stock-based compensation on stock options, RSUs & RSAs

 

 

 

 

 

 

 

 

 

 

-

 

 

 

-

 

 

 

258,691

 

 

 

-

 

 

 

-

 

 

 

258,691

 

Foreign currency translation adjustment

 

 

 

 

 

 

 

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

259,973

 

 

 

-

 

 

 

259,973

 

Net loss 

 

 

 

 

 

 

 

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(1,713,663 )

 

 

(1,713,663 )

Balances at December 31, 2023

 

 

 

 

 

 

 

 

 

 

37,549,378

 

 

$ 375,494

 

 

$ 243,475,209

 

 

$ 741,301

 

 

$ (210,892,268 )

 

$ 33,699,736

 

Issuance of common stock for:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Employee Stock Purchase Plan

 

 

 

 

 

 

 

 

 

 

15,840

 

 

 

158

 

 

 

19,800

 

 

 

-

 

 

 

-

 

 

 

19,958

 

Exercise of Stock Options, RSUs & RSAs, net

 

 

 

 

 

 

 

 

 

 

225,814

 

 

 

2,258

 

 

 

(2,258 )

 

 

-

 

 

 

-

 

 

 

 

 

Issuance of common stock for acquisition of Visimid

 

 

 

 

 

 

 

 

 

 

267,176

 

 

 

2,672

 

 

 

333,382

 

 

 

-

 

 

 

-

 

 

 

336,054

 

Issuance of common stock under public equity placement

 

 

 

 

 

 

 

 

 

 

68,041

 

 

 

680

 

 

 

97,528

 

 

 

-

 

 

 

-

 

 

 

98,208

 

Stock-based compensation on stock options, RSUs & RSAs

 

 

 

 

 

 

 

 

 

 

-

 

 

 

-

 

 

 

264,492

 

 

 

-

 

 

 

-

 

 

 

264,492

 

Foreign currency translation adjustment

 

 

 

 

 

 

 

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(112,356 )

 

 

-

 

 

 

(112,356 )
Net loss 

 

 

 

 

 

 

 

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(2,597,534 )

 

 

(2,597,534 )
Balances at March 31, 2024 

 

 

 

 

 

 

 

 

 

 

38,126,249

 

 

$ 381,262

 

 

$ 244,188,153

 

 

$ 628,945

 

 

$ (213,489,802 )

 

$ 31,708,558

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock for:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercise of Stock Options, RSUs & RSAs, net

 

 

 

 

 

 

 

 

 

 

610,952

 

 

 

6,110

 

 

 

(6,110 )

 

 

-

 

 

 

-

 

 

 

-

 

Issuance of common stock under public equity placement

 

 

 

 

 

 

 

 

 

 

517,442

 

 

 

5,174

 

 

 

702,950

 

 

 

-

 

 

 

-

 

 

 

708,124

 

Stock-based compensation on stock options, RSUs & RSAs

 

 

 

 

 

 

 

 

 

 

-

 

 

 

-

 

 

 

255,765

 

 

 

-

 

 

 

-

 

 

 

255,765

 

Foreign currency translation adjustment

 

 

 

 

 

 

 

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(119,009 )

 

 

-

 

 

 

(119,009 )
Net loss

 

 

 

 

 

 

 

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(2,353,773 )

 

 

(2,353,773 )
Balances at June 30, 2024

 

 

 

 

 

 

 

 

 

 

39,254,643

 

 

$ 392,546

 

 

$ 245,140,758

 

 

$ 509,936

 

 

$ (215,843,575 )

 

$ 30,199,665

 

 

 
8

 

 

LIGHTPATH TECHNOLOGIES, INC.

Condensed Consolidated Statements of Cash Flows

(unaudited)

 

 

 

Nine Months Ended March 31,

 

 

 

2025

 

 

2024

 

Cash flows from operating activities:

 

 

 

 

 

 

Net loss

 

$ (7,795,091 )

 

$ (5,653,573 )
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

3,356,752

 

 

 

2,985,850

 

Interest from amortization of loan issuance costs

 

 

161,905

 

 

 

-

 

Loss on extinguishment of debt

 

 

418,502

 

 

 

-

 

Warrant issuance costs

 

 

318,777

 

 

 

-

 

Change in fair value of warrant liability

 

 

(904,694 )

 

 

-

 

Loss on disposal of property and equipment

 

 

80,505

 

 

 

13,248

 

Stock-based compensation on stock options, RSUs & RSAs, net

 

 

745,155

 

 

 

763,258

 

Provision for credit losses

 

 

(3,014 )

 

 

(4,422 )

Change in operating lease assets and liabilities

 

 

(91,582 )

 

 

47,693

 

Inventory write-offs to allowance

 

 

135,625

 

 

 

95,539

 

Deferred taxes

 

 

(2,368 )

 

 

8,573

 

Changes in operating assets and liabilities, net of acquisitions:

 

 

 

 

 

 

 

 

Trade accounts receivable

 

 

(822,043 )

 

 

1,766,594

 

Other current assets

 

 

73,362

 

 

 

(419,797 )

Inventories

 

 

(1,206,340 )

 

 

725,460

 

Prepaid expenses and deposits

 

 

(360,439 )

 

 

95,900

 

Accounts payable and accrued liabilities

 

 

520,289

 

 

 

32,020

 

Net cash (used in) provided by operating activities

 

 

(5,374,699 )

 

 

456,343

 

 

 

 

 

 

 

 

 

 

Cash flows from investing activities:

 

 

 

 

 

 

 

 

Purchase of property and equipment

 

 

(580,726 )

 

 

(1,892,660 )
Proceeds from sale of equipment

 

 

10,648

 

 

 

-

 

Proceeds from sale-leaseback of equipment

 

 

-

 

 

 

364,710

 

Acquisition of G5

 

 

(20,250,011 )

 

 

-

 

Acquisition of Visimid, net of cash acquired

 

 

-

 

 

 

(847,141 )

Net cash used in investing activities

 

 

(20,820,089 )

 

 

(2,375,091 )

 

 

 

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

 

 

 

Proceeds from exercise of stock options

 

 

3,175

 

 

 

-

 

Proceeds from sale of common stock from Employee Stock Purchase Plan

 

 

14,385

 

 

 

39,677

 

Proceeds from issuance of common stock under public equity placement

 

 

-

 

 

 

98,208

 

Proceeds from issuance of common stock under private equity placement

 

 

437,725

 

 

 

-

 

Proceeds from issuance of preferred stock under private equity placement

 

 

18,842,138

 

 

 

-

 

Proceeds from issuance of warrants under private equity placement

 

 

4,313,813

 

 

 

-

 

Deferred payment for acquisition of Visimid

 

 

(125,000 )

 

 

-

 

Borrowings on loans payable

 

 

6,659,596

 

 

 

142,853

 

Loan issuance costs

 

 

(597,465 )

 

 

-

 

Payments on loans payable

 

 

(149,118 )

 

 

(2,262,798 )

Repayment of finance lease obligations

 

 

(133,711 )

 

 

(87,610 )

Net cash provided by (used in) financing activities

 

 

29,265,538

 

 

 

(2,069,670 )

 

 

 

 

 

 

 

 

 

Effect of exchange rate on cash and cash equivalents

 

 

(72,133 )

 

 

2,880

 

Change in cash, cash equivalents and restricted cash

 

 

2,998,617

 

 

 

(3,985,538 )
Cash, cash equivalents and restricted cash, beginning of period

 

 

3,480,268

 

 

 

7,144,490

 

Cash, cash equivalents and restricted cash, end of period

 

$ 6,478,885

 

 

$ 3,158,952

 

 

 

 

 

 

 

 

 

 

Supplemental disclosure of cash flow information:

 

 

 

 

 

 

 

 

Interest paid in cash

 

$ 66,136

 

 

$ 161,676

 

Income taxes paid

 

$ 118,016

 

 

$ 120,787

 

Supplemental disclosure of non-cash investing & financing activities:

 

 

 

 

 

 

 

 

Purchase of equipment through finance lease arrangements

 

$ 93,048

 

 

$ 391,107

 

Issuance of common stock for acquisition of Visimid

 

$ 713,946

 

 

$ 486,054

 

 

 
9